It seems pretty obvious that once a company figures out a winning formula, it ought to stick with it. Acquisitions have definitely done a lot to build and boost specialty pharmaceutical company Valeant (NYSE:VRX). Now the company is going to the well again to acquire Medicis (NYSE:MRX).
While there's always a risk that Valeant will eventually bite off more
than it can chew, this deal looks like a winner from the get-go.